Please assess the completion status of the following clinical trial:

Trial Title: Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients receiving a cadaveric single kidney transplant~* patients on a standard immunosuppressive regime~Exclusion Criteria:~* patients on different immunosuppressives~* patients receiving 3rd or subsequent kidney transplant~* patients are fully anti-coagulated~* patients unable to take Heme Arginate~* patients unable to give informed consent~* patients on combined anti-platelet agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heme arginate (Normosang) (Type: ACTIVE_COMPARATOR): This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
- 0.9% saline (Type: PLACEBO_COMPARATOR): The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).